Bexson Biomedical
Developer of a subcutaneous ketamine delivery system designed to address the limitations of current ketamine preparations to allow control of overdosing and reduced the need for monitoring.
1
Funding Rounds
$4.8m
Money raised
Overview
Developer of a subcutaneous ketamine delivery system designed to address the limitations of current ketamine preparations to allow control of overdosing and reduced the need for monitoring.
- Website:
- Social accounts: linkedin
Funding series
Funding Series Analysis
The company Bexson Biomedical has raised a total of $4.8m in funding over 1 rounds.
Key Insights:
- Bexson Biomedical Series A round, February 2021: $4.8m
Bexson Biomedical Series A round, February 2021
$4.8m
Industries
Bexson Biomedical is active in the following industries: